Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee

Executive Summary

Next fiscal year will be a good one to redeem a voucher, and probably to qualify for one as well.


Related Content

Priority Review Voucher Fee Rises 4.6% For Fiscal 2018
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations
Pediatric Rare Disease Voucher Program Faces Expiration
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Tracking The Priority Review Vouchers
Orphan Designation Requests To Get Slower Reviews
FDA Wouldn't Get Funding Boost As Part Of Senate GOP Innovation Bill
Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says
FDA Priority Review Costs Remain Stable While Voucher Fee Ticks Up


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts